(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients Who Receive Neurotoxic Therapy
- Central nervous system toxicity is a recognized side effect of certain cancer
therapies, particularly cranial irradiation, intrathecal therapy and systemic high-dose
- The pathophysiologic mechanisms are not well-defined and clinical manifestations vary.
Previous studies defining MRI changes and correlating these with neurocognitive
deficiencies have been inconsistent.
- Recent advances in brain imaging may help to better define neurotoxic effects.
(1)H-NMRS is a noninvasive method of obtaining in vivo biochemical information from the
brain. It has been used to study patients with CNS disorders, including neuronal
-To identify specific patterns of brain metabolites that are associated with therapy-related
neurotoxicity using (1)H-NMRS in cancer patients who are receiving or have received
potentially neurotoxic therapy.
-Patients with brain tumors or patients receiving high-dose systemic chemotherapy,
intrathecal chemotherapy (lumbar puncture or intra-Ommaya), or cranial radiation therapy OR
patients with documented or suspected clinical neurotoxicity presumed to be caused by
treatment for cancer.
- In order to identify metabolite profiles that may be associated with neurotoxicity,
NMRS data will be collected in a cross-sectional manner from patients at various stages
of treatment and longitudinally throughout the course of therapy.
- NMRS studies will be performed on patients entered on this study at any or all of the
following times: prior to therapy, immediately after the first cycle of therapy, prior
to subsequent cycles of therapy, or after completion of all therapy.
- Neurotoxicity will also be evaluated by neuropsychological testing.
Katherine E Warren, M.D.
National Cancer Institute (NCI)
United States: Federal Government
|National Institutes of Health Clinical Center, 9000 Rockville Pike
|Bethesda, Maryland 20892